-
181
Change in Lipofectamine Carrier as a Tool to Fine-Tune Immunostimulation of Nucleic Acid Nanoparticles
Published 2023-06-01“…Nucleic acid nanoparticles (NANPs) require a carrier to allow for their intracellular delivery to immune cells. …”
Get full text
Article -
182
Anti-sporozoite antibodies and immunity to malaria in a rural Gambian population.
Published 1988“…A conserved repeated epitope, (NANP)3, of the circumsporozoite protein of Plasmodium falciparum has been identified previously as a putative target for artificially induced immunity to malaria. …”
Journal article -
183
Natural parasite exposure induces protective human anti-malarial antibodies.
Published 2017“…Antibodies against the NANP repeat of circumsporozoite protein (CSP), the major surface antigen of Plasmodium falciparum (Pf) sporozoites, can protect from malaria in animal models but protective humoral immunity is difficult to induce in humans. …”
Journal article -
184
Opportunities, Barriers, and a Strategy for Overcoming Translational Challenges to Therapeutic Nucleic Acid Nanotechnology
Published 2021“…Significant progress in the development, production, and characterization of nucleic acid nanomaterials and nucleic acid nanoparticles (NANPs), as well as abundant proof-of-concept data, are paving the way toward biomedical applications of these materials. …”
Get full text
Article -
185
Opportunities, Barriers, and a Strategy for Overcoming Translational Challenges to Therapeutic Nucleic Acid Nanotechnology
Published 2021“…Significant progress in the development, production, and characterization of nucleic acid nanomaterials and nucleic acid nanoparticles (NANPs), as well as abundant proof-of-concept data, are paving the way toward biomedical applications of these materials. …”
Get full text
Article -
186
High sporozoite antibody titers in conjunction with microscopically detectable blood infection display signatures of protection from clinical malaria
Published 2017“…Although naturally acquired humoral responses against Pfspz and (NANP)5 were strongly correlated (p < 0.0001), 37% of Pfspz responders did not recognize (NANP)5. …”
Journal article -
187
High-density binding to Plasmodium falciparum circumsporozoite protein repeats by inhibitory antibody elicited in mouse with human immunoglobulin repertoire.
Published 2022-11-01“…Like other IGHV3-33/IGKV1-5-encoded anti-NANP antibodies, mAb 850 primarily utilizes its HCDR3 and germline-encoded aromatic residues to recognize its core NANP motif. …”
Get full text
Article -
188
Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection
Published 2021-08-01“…NANP6 IgG3 magnitude, CSP IgG1 magnitude, and total serum antibody dissociation phase area-under-the-curve for NANP6, CSP, NPNA3, and N-interface binding were also associated with protection status in the regimen adjusted univariate analysis. …”
Get full text
Article -
189
Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.
Published 2005“…This regimen induced anti-NANP antibodies in 10/11 and modest T cell responses. …”
Journal article -
190
Development of antimalarial human monoclonal antibodies against Plasmodium falciparum
Published 2022“…CSP has three domains: an N-terminus, a central region composed of repeating NPDP/NVDP/NANP tetrapeptides, and a C-terminus. A truncated form of CSP containing 19 NANP repeats and the C-terminus is the antigenic target of the world’s only approved malaria vaccine (RTS,S). …”
Thesis -
191
Investigating protective mechanisms of anti-sporozoite vaccines
Published 2023“…R21 is a virus-like particle-based (VLP-based) vaccine displaying the immunodominant NANP repeat region of the circumsporozoite protein (CSP) of <em>Plasmodium falciparum</em>. …”
Thesis -
192
Vaksin malaria dan perkembangannya
Published 1990“…Later it was found that the sequence of NANP in the CS gene predominates with minor repeats of NVDP. …”
Article -
193
A multivalent Plasmodium falciparum circumsporozoite protein‐based nanoparticle malaria vaccine elicits a robust and durable antibody response against the junctional epitope and th...
Published 2023-07-01“…We report the design of a SpyCatcher‐mi3‐nanoparticle‐based vaccine presenting multiple copies of a chimeric PfCSP (cPfCSP) antigen that incorporates these important “T1/junctional” epitopes as well as a reduced number of (NANP)n repeats. cPfCSP‐SpyCatcher‐mi3 was immunogenic in mice eliciting high and durable IgG antibody levels as well as a balanced antibody response against the T1/junctional region and the (NANP)n repeats. …”
Get full text
Article -
194
Epitope-coated polymer particles elicit neutralising antibodies against Plasmodium falciparum sporozoites
Published 2021-11-01“…Abstract The current Malaria RTS,S vaccine is based on virus-like particles (VLPs) comprising the NANP repetitive epitopes from the cicumsporozoite protein (CSP) of Plasmodium falciparum. …”
Get full text
Article -
195
Identification of a neutralizing epitope within minor repeat region of Plasmodium falciparum CS protein
Published 2021-01-01“…In contrast, murine monoclonal antibodies specific for the major CS repeats (NANP)n could be isolated from peptide-immunized mice that had limited or no sporozoite-neutralizing activity. …”
Get full text
Article -
196
A VLP for validation of the Plasmodium falciparum circumsporozoite protein junctional epitope for vaccine development
Published 2021-04-01“…Peptides from PfCSP, particularly from outside the normal target of neutralizing antibodies, the central NANP repeat region, are screened for evidence of protective efficacy. …”
Get full text
Article -
197
-
198
Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaq...
Published 2020-01-01“…One month after the last vaccination all study participants had seroconverted to the PfCSP (NANP)6, and the PfCSP Full Length (N + C-Terminal). …”
Get full text
Article -
199
Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaq...
Published 2019“…One month after the last vaccination all study participants had seroconverted to the PfCSP (NANP)6, and the PfCSP Full Length (N + C-Terminal). …”
Journal article -
200
Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein.
Published 2021-12-01“…These C-CSP-specific mAbs had limited binding to sporozoites in vitro that was increased by combination with neutralizing human "repeat" mAbs against the NPDP/NVDP/NANP tetrapeptides in the central repeat region of PfCSP. …”
Get full text
Article